Virtus ETF Advisers LLC Amylyx Pharmaceuticals, Inc. Transaction History

Virtus ETF Advisers LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $10,078 - $72,780	3,719 Added 16.81%	25,849 $73,000
Q4 2023 Feb 15, 2024	BUY	$12.07 - $18.46 $119,577 - $182,883	9,907 Added 81.05%	22,130 $325,000
Q3 2023 Nov 07, 2023	SELL	$18.08 - $23.45 $28,620 - $37,121	-1,583 Reduced 11.47%	12,223 $223,000
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $112,159 - $167,971	5,346 Added 63.19%	13,806 $297,000
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $4,239 - $6,262	153 Added 1.84%	8,460 $248,000
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $247,133 - $326,132	8,307 New	8,307 $306,000

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $310M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.